By Matt Grossman

GlaxoSmithKline PLC and Medicago are beginning a Phase 3 trial to test a Covid-19 vaccine that they are developing, the companies said Tuesday.

Canada-based Medicago is responsible for the vaccine to be tested in the trial, while GlaxoSmithKline developed the adjuvant. In the trial, two doses will be given 21 days apart. Up to 30,000 people will be enrolled in the placebo-controlled study.

Medicago has also begun a study to explore developing an additional vaccine candidate to address Covid-19 variants.

The decision to begin a Phase 3 trial portion follows positive interim Phase 2 results, Medicago and GlaxoSmithKline said. Full results from the Phase 2 portion will be available next month, according to the companies.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

March 16, 2021 07:43 ET (11:43 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
過去 株価チャート
から 3 2024 まで 4 2024 Gskのチャートをもっと見るにはこちらをクリック
Gsk (LSE:GSK)
過去 株価チャート
から 4 2023 まで 4 2024 Gskのチャートをもっと見るにはこちらをクリック